If they get efficacy with a different dosage for >65's then I'm hoping they revisit COPD too - most COPD sufferers are in that age bracket, current dosage showed a stemming of the decline in the 6MWT but not enough for the world to get excited about (personally I would have loved my Dad to have had access to a biologic that stemmed the decline as his heart was strong but the inexorable decline of his lung tissue due to inflammatory exacerbations just meant that he was repeatedly hospitalised for intravenous antibiotics and steroids - a good secondary endpoint there would be recurrent hospitalisation).
I'm also wondering if they have any data on long covid - would be nice to know if Rem-L can improve the symptoms of those that continue to suffer.
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |